Intas launches Thymotas - A potential Immuno-Booster in the pandemic times

Thymotas is a patented research formulation that fortifies immunity and fights infections

A Global Healthcare Partner

Intas is trusted by healthcare professionals across more than 85 countries across the globe

A Dynamic Product Basket

Empowered by a passionate R&D Team, Intas has one of the strongest product portfolios in the world​

Growth is in our Nature

One of the fastest growing pharmaceutical companies​

To know more about Thymotas, >click here

Intas Pharmaceuticals Ltd.


Intas is one of the leading multinational pharmaceutical formulation development, manufacturing and marketing companies in the world. Today, Intas is present in more than 85 countries worldwide and is growing at ~20% CAGR. Around 70% of its revenues come from the international markets, particularly the highly regulated markets of EU and US. At Intas, every day and everyone works to create a world of good health, happiness and hope.

Read More

Excellence is a Matter of Fact

Transforming Science into Smiles


Research and Development

R & D is at the heart of Intas’ success. A highly qualified team works round the clock with a quest to develop a progressive threefold product basket that includes world-class generics, oncology and parenteral as well as added-value products (AVPs).

  • 6-7% of turnover invested in R & D, year on year
  • Over 1,00,000 sq ft dedicated R&D space
  • 550+ Scientists and Researchers
  • 17 Advanced Facilities
  • Global Regulatory Authority Accreditations
  • Pioneer in Biosimilars
read more

Latest News


Media
12, December 2018

INTAS launches THYMOTAS - a patented, powerful immuno-booster add-on to standard COVID-19 treatment

Read More
Media
12, December 2018

INTAS Develops COVID-19 Hyperimmune Globulin - A New Treatment

Read More
Media
12, December 2018

Intas Pharmaceuticals becomes the first to launch Romiplostim in India, revolutionizing chronic immune thrombocytopenia (ITP) therapy.

Read More